Thermo Fisher Scientific Inc. has announced the expansion of its strategic partnership with Sanofi through the planned acquisition of Sanofi’s sterile manufacturing site in Ridgefield, New Jersey. The move aims to increase U.S.-based drug product manufacturing capacity. Specific terms of
Quotient Sciences, a contract research, development, and manufacturing organisation (CRDMO), has announced the formation of its first Scientific Advisory Board (SAB), with four distinguished experts appointed as founding members. The SAB aims to strengthen the company’s commitment to scientific excellence
Made Scientific, a U.S.-based cell therapy CDMO, has announced a strategic partnership with Sentinel BioTherapeutics, a clinical-stage biotechnology company, to support the development of SENT-001, an encapsulated cell-based immunotherapy targeting solid tumours. The agreement focuses on SENT-001, a genetically engineered,
Zhaoke Ophthalmology Limited has signed a memorandum of agreement (MOA) with France-based FAREVA Group, a contract manufacturing organisation serving pharmaceutical, beauty, and industrial markets. Under the agreement, Zhaoke becomes the recommended partner for FAREVA customers seeking pharmaceutical manufacturing solutions in
AATec Medical GmbH and Northway Biotech have announced a partnership to develop the industrial production process for ATL-105, AATec’s lead inhaled biologic therapy for respiratory diseases. The agreement focuses on manufacturing process and analytical development for ATL-105, which is based
LOTTE BIOLOGICS, a contract development and manufacturing organisation (CDMO), has signed a Memorandum of Understanding (MOU) with AbTis, a specialist in antibody-drug conjugates (ADCs), to co-develop next-generation ADC technologies. The companies plan to combine AbTis’s AbClick® linker platform with LOTTE
PCI Pharma Services, a global contract development and manufacturing organisation (CDMO), has announced a new strategic investment to accelerate its growth and service expansion. The investment is co-led by Bain Capital and existing lead investor Kohlberg, with significant reinvestment from
Cellular Origins, a TTP company specialising in robotic manufacturing for cell and gene therapies (CGTs), has joined forces with CGT Catapult and Resolution Therapeutics to launch a new consortium project backed by a £1 million Smart Grant from Innovate UK.
I Peace, Inc., a GMP-compliant CDMO specialising in induced pluripotent stem cells (iPSCs), has entered into a collaboration with US-based Vita Therapeutics to co-develop universal iPS cell lines intended for use in allogeneic cell transplantation therapies. The project will utilise
Flamma, a global contract development and manufacturing organisation (CDMO), has announced the grand opening of a new current Good Manufacturing Practice (cGMP) facility in Dalian, China. The plant will enhance the company’s capacity to produce and commercialise small molecule active
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups Sign up for our weekly newsletter
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
